Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21576141 | 0.83 | POLQ (0.47) | POLQALDH1A1MAOBMAOAPPARG | |
| SCHEMBL19286778 | 0.82 | PPARG (0.44) | POLQALDH1A1PPARGEPHX2HDAC1 | |
| SCHEMBL31173765 | 0.81 | POLQ (0.59) | POLQALDH1A1MAOBMAOARBP4 | |
| SCHEMBL265536 | 0.81 | POLQ (0.59) | POLQALDH1A1MAOBMAOARBP4 | |
| SCHEMBL6864363 | 0.81 | POLQ (0.58) | POLQALDH1A1MAOBMAOARBP4 | |
| SCHEMBL21100044 | 0.80 | CYP1A2 (0.52) | ALDH1A1KDM4EGAATDP1 | |
| Methyl Alcohol SCHEMBL8011354 | 0.80 | POLQ (0.62) | POLQALDH1A1MAOBMAOAOPRK1 | |
| SCHEMBL187791 | 0.79 | POLQ (0.61) | POLQALDH1A1MAOBMAOARBP4 | |
| SCHEMBL29718585 | 0.79 | POLQ (0.61) | POLQALDH1A1MAOBMAOARBP4 | |
| SCHEMBL6971669 | 0.79 | POLQ (0.57) | POLQALDH1A1MAOBMAOARBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
| WO-2020023355-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-30 | — | — | WO | disclosed |
| US-9758492-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160200674-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | POLQ 3559/4885ALDH1A1 857/4885MAOB 1661/4885 |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | POLQ 3042/4885ALDH1A1 373/4885MAOB 11/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | POLQ 4011/4885ALDH1A1 982/4885MAOB 735/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | POLQ 3559/4885ALDH1A1 857/4885MAOB 1661/4885 |
| US-20160200674-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | POLQ 2519/4885ALDH1A1 996/4885MAOB 60/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | POLQ 3087/4885ALDH1A1 3634/4885MAOB 4131/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | POLQ 4252/4885ALDH1A1 963/4885MAOB 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.